Investigating the molecular mechanism of iguratimod act on SLE using network pharmacology and molecular docking analysis.

ABSTRACT: Objective: Iguratimod (IGU) is a novel small disease-modifying compound widely used in Asia for the treatment of rheumatic diseases. IGU is a methane sulfonanilide. We applied network pharmacology to investigate the pharmacological mechanisms of IGU act on SLE. Methods: We used PharmMapper, UniProt, and OMIM databases to screen the potential targets of IGU, and the SLE-related disease targets were predicted. Hub target genes among the intersections of the potential targets (IGU) and related genes (SLE) were validated using the PPI network generated by the String database. GO and KEGG enrichment analyses were carried out using the David online platform. Finally, the molecular docking of hub targets and their corresponding compounds were compl

SUBMITTER: Zeng H 

PROVIDER: S-EPMC9580962 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature